We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Stamp-Sized Microfluidic Chip Uses Programmed Magnetic Nanobeads and Off-the-Shelf Cellphone to Diagnose COVID-19

By LabMedica International staff writers
Posted on 26 Feb 2021
A new testing system uses programmable magnetic nanobeads, an off-the-shelf cellphone and a plug-in diagnostic tool to diagnose COVID-19 in 55 minutes or less.

Researchers at Rice University (Houston, TX, USA) have developed a stamp-sized microfluidic chip that measures the concentration of SARS-CoV-2 nucleocapsid (N) protein in blood serum from a standard finger prick. More...
The nanobeads bind to SARS-CoV-2 N protein, a biomarker for COVID-19, in the chip and transport it to an electrochemical sensor that detects minute amounts of the biomarker. The researchers argue their process simplifies sample handling compared to swab-based PCR tests that are widely used to diagnose COVID-19 and need to be analyzed in a laboratory.

The new tool relies on a slightly more complex detection scheme but delivers accurate, quantitative results in a short amount of time. To test the device, the lab relied on donated serum samples from people who were healthy and others who were COVID-19-positive. According to the researchers, a longer incubation yields more accurate results when using whole serum. The lab found that 55 minutes was an optimum amount of time for the microchip to sense SARS-CoV-2 N protein at concentrations as low as 50 picograms (billionths of a gram) per milliliter in whole serum. The microchip could detect N protein in even lower concentrations, at 10 picograms per milliliter, in only 25 minutes by diluting the serum fivefold. Paired with a Google Pixel 2 phone and a plug-in potentiostat, it was able to deliver a positive diagnosis with a concentration as low as 230 picograms for whole serum.

A capillary tube is used to deliver the sample to the chip, which is then placed on a magnet that pulls the beads toward an electrochemical sensor coated with capture antibodies. The beads bind to the capture antibodies and generate a current proportional to the concentration of biomarker in the sample. The potentiostat reads that current and sends a signal to its phone app. If there are no COVID-19 biomarkers, the beads do not bind to the sensor and get washed away inside the chip. The researchers believe that it would not be difficult for industry to manufacture the microfluidic chips or to adapt them to new COVID-19 strains if and when that becomes necessary.

“What’s great about this device is that doesn’t require a laboratory,” said Peter Lillehoj, a mechanical engineer at Rice lab where the system was developed. “You can perform the entire test and generate the results at the collection site, health clinic or even a pharmacy. The entire system is easily transportable and easy to use.”

Related Links:
Rice University


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.